ApoPharma's Ferriprox Gamble Pays Off In Panel Vote, But What About FDA?
Executive Summary
ApoPharma's risky move in not complying with FDA's request for an additional randomized controlled trial of its iron overload treatment Ferriprox (deferiprone) paid off in a lopsided advisory panel vote in favor of approval, but the agency has yet to give the final word.